AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

April 23, 2026 - 00:48

Amgen has announced the retirement of Dr. David M. Reese, the company's Executive Vice President and Chief Technology Officer. The decision is effective as of the end of this year, concluding a significant chapter in Amgen's research and development leadership.

Dr. Reese has been a pivotal figure at Amgen for over a decade, overseeing the global research and development organization. His tenure was marked by a focus on advancing Amgen's pipeline of innovative medicines across a range of serious diseases, including cancer, cardiovascular conditions, and inflammation. Company officials credited his scientific and medical expertise with being instrumental in progressing numerous therapeutic candidates from early discovery through to clinical development and regulatory approval.

The search for a successor to this critical leadership role is now underway. Amgen stated that the transition period will be used to ensure a smooth handover of responsibilities. The company expressed its gratitude for Dr. Reese's many contributions and his dedicated service, which helped strengthen Amgen's foundation in biotechnology and its commitment to serving patients worldwide. His departure marks the end of an era for the company's R&D division as it looks toward its next phase of scientific innovation.